Fulzerasib (GFH-925): A Comprehensive Analysis of a Next-Generation KRAS G12C Inhibitor

Executive Summary

Fulzerasib (GFH-925) is a potent, selective, orally active, and irreversible covalent inhibitor of the KRAS G12C oncoprotein, a therapeutic target that has historically presented significant challenges in drug development.[1] Developed from a novel chemical scaffold, fulzerasib has demonstrated a highly compelling clinical profile that positions it as a formidable agent in the treatment of KRAS G12C-mutated solid tumors. This report provides a comprehensive analysis of its molecular characteristics, mechanism of action, extensive clinical trial data, regulatory trajectory, and strategic positioning within the competitive landscape.

The clinical efficacy of fulzerasib is a standout feature of its profile. In the first-line treatment of Non-Small Cell Lung Cancer (NSCLC), a combination of fulzerasib with the EGFR inhibitor cetuximab yielded an exceptional Objective Response Rate (ORR) of approximately 80% and a median Progression-Free Survival (PFS) of 12.5 months in the KROCUS study, setting a new benchmark for chemo- and immune-free regimens.[4] As a monotherapy in heavily pre-treated patient populations, fulzerasib has shown robust and durable activity. In second-line and later NSCLC, it achieved a confirmed ORR of 49.1% and a median PFS of 9.7 months, leading to its regulatory approval in China.[6] Furthermore, it has demonstrated remarkable efficacy in metastatic Colorectal Cancer (CRC), a setting where other inhibitors have shown modest single-agent activity, with a confirmed ORR of 44.6% and a median PFS of 8.1 months.[8] A critical differentiator is its significant activity against intracranial tumors, addressing the challenging issue of brain metastases.[4]

Complementing its potent efficacy is a differentiated and highly manageable safety profile. A key advantage over existing KRAS G12C inhibitors is a notably lower incidence of gastrointestinal toxicities, such as nausea and diarrhea.[8] This favorable tolerability minimizes overlapping toxicities and makes fulzerasib an ideal partner for combination therapies, enhancing its strategic value. While hematologic events like anemia are observed, they have proven to be manageable, with very low rates of treatment discontinuation due to adverse events across clinical trials.

Fulzerasib's development has been marked by a rapid and successful regulatory journey. In August 2024, it received approval from China's National Medical Products Administration (NMPA) under the brand name Dupert® for previously treated NSCLC, making it the first domestically developed and third globally approved KRAS G12C inhibitor.[6] The drug has also received multiple Breakthrough Therapy Designations (BTDs) from the NMPA for both NSCLC and CRC, and the U.S. Food and Drug Administration (FDA) has cleared a global Phase III registrational trial for fulzerasib monotherapy in refractory CRC.[11]

Strategically, fulzerasib is positioned not merely to compete with but potentially to establish a new standard of care for KRAS G12C-mutant cancers. Its combination of potentially best-in-class efficacy and a superior safety profile provides a compelling value proposition. The data suggest fulzerasib could become the preferred agent in its class, capable of displacing first-generation inhibitors and capturing significant market share. Its continued development in global trials and exploration in novel combinations herald its emergence as a pivotal therapy in precision oncology.

Molecular Profile and Developmental Rationale

The foundation of fulzerasib's clinical success lies in its unique molecular architecture and a series of strategic corporate decisions that have guided its development from a novel chemical entity to a market-approved therapeutic. This section details its chemical identity, the rationale behind its structural design, and the key partnerships propelling its global trajectory.

Nomenclature and Chemical Identity

Fulzerasib is identified by a variety of names and codes across research, regulatory, and commercial contexts, reflecting its progression through the drug development pipeline. A consolidated list of its identifiers is essential for tracking and cross-referencing information.

• Research and Development Codes: The primary research code is GFH-925. In its collaboration with Innovent Biologics, it is also referred to as IBI351.[1]
• International Nonproprietary Name (INN): The officially recognized generic name is fulzerasib.[1]
• Brand Name: Following its approval in China, it is marketed under the trade name Dupert®.[1]
• DrugBank ID: The compound is cataloged in the DrugBank database under the accession number DB17481 [User Query].
• CAS Registry Number: Its unique Chemical Abstracts Service number is 2641747-54-6.[13]

Fulzerasib is classified as a synthetic organic, small molecule drug, designed for oral administration.[1]

Structural and Physicochemical Properties

The distinct clinical profile of fulzerasib is a direct result of its novel chemical structure, which was engineered through a deliberate, structure-based drug design strategy to optimize its therapeutic properties.

The core of the molecule is a novel lactam-based tetracyclic naphthyridinone scaffold.[15] This unique architecture was created using a conformation-driven cyclization strategy. The primary goal of this design was to achieve optimal pharmacokinetic properties, specifically low clearance, high systemic exposure, and excellent oral bioavailability, which are critical for an effective and well-tolerated oral cancer therapy.[17]

The molecule's physicochemical properties are summarized in Table 1. Its molecular formula is C32​H30​ClFN6​O4​, and its molecular weight is consistently reported in the range of 616.2 to 617.08 g/mol.[1] A crucial aspect of its design is its adherence to Lipinski's Rule of Five, a widely used guideline to predict the "druglikeness" of a chemical compound. Fulzerasib breaks zero of these rules, which strongly predicts good membrane permeability and oral bioavailability, a property that has been validated in both preclinical and clinical settings.[1]

Table 1: Drug Identity and Physicochemical Properties of Fulzerasib
Identifier	Value
International Nonproprietary Name (INN)	Fulzerasib 15
Brand Name (China)	Dupert® 6
Research Codes	GFH-925, IBI351 1
DrugBank ID	DB17481 [User Query]
CAS Number	2641747-54-6 16
Chemical Formula	C32​H30​ClFN6​O4​ 13
Molecular Weight	616.2 g/mol 14
Canonical SMILES	C=CC(=O)N1CCN2C@HC(=O)N(c1c2c2cc(Cl)c(nc2n(c1=O)c1c(C)ccnc1C(C)C)c1c(O)cccc1F)C
InChI Key	PYKBFRQMXJWLGG-OAQYLSRUSA-N
Physicochemical Properties
Hydrogen Bond Acceptors	8
Hydrogen Bond Donors	1
Rotatable Bonds	5
Topological Polar Surface Area (TPSA)	111.35 A˚2
XLogP	4.42
Lipinski's Rules Broken	0

The deliberate engineering of this novel scaffold is a primary driver of fulzerasib's differentiated clinical profile. The structure was not an accidental discovery but the result of a rational design process aimed at solving the pharmacokinetic challenges that can plague oral inhibitors. This successful chemical design has translated directly into tangible clinical benefits, most notably a favorable safety profile characterized by low gastrointestinal toxicity, which provides a significant competitive advantage over other drugs in its class.

Developmental Genesis and Strategic Partnerships

Fulzerasib was discovered and initially developed by GenFleet Therapeutics, a clinical-stage biotechnology company based in Shanghai, China, with a focus on oncology and immunology. Recognizing the significant potential of the asset, GenFleet has executed a shrewd, multi-pronged partnership strategy to accelerate its development and maximize its global commercial potential.

1. Partnership with Innovent Biologics for Greater China: In September 2021, GenFleet entered into a pivotal exclusive license agreement with Innovent Biologics, a major Chinese biopharmaceutical company with extensive clinical development and commercialization infrastructure. The deal granted Innovent the rights to develop and commercialize fulzerasib in mainland China, Hong Kong, Macau, and Taiwan. The terms included a $22 million upfront payment to GenFleet, with the potential for up to $240 million in milestone payments plus tiered royalties. This partnership provided the financial resources and operational expertise needed to rapidly advance fulzerasib through late-stage trials in China, culminating in its successful NMPA approval.
2. Collaboration with Merck for European Combination Studies: In December 2022, GenFleet announced a clinical trial collaboration and supply agreement with the global pharmaceutical giant Merck. This agreement was specifically for a clinical study combining fulzerasib with Merck's well-established anti-EGFR antibody, ERBITUX® (cetuximab). This collaboration led to the KROCUS trial, a multi-center study in Europe investigating the combination as a first-line treatment for NSCLC patients with the KRAS G12C mutation.

This dual-partnership strategy reflects a highly effective and de-risked approach to global drug development. By partnering with a regional powerhouse like Innovent, GenFleet secured a fast-track to the major Chinese market, ensuring near-term regulatory success and revenue potential. Simultaneously, by retaining ex-China rights and collaborating with a global leader like Merck for a high-impact combination study, GenFleet was able to validate the drug's potential in a global setting. This bifurcated approach has successfully maximized the asset's value, proving its efficacy and safety in different populations and therapeutic settings, and paving the way for a broader global launch.

Mechanism of Action and Preclinical Validation

The therapeutic efficacy of fulzerasib is rooted in its precise molecular mechanism, which targets a specific oncogenic driver that was long considered intractable. Its progression into clinical trials was supported by a robust preclinical data package that not only validated its mechanism but also predicted its ultimate clinical advantages.

Targeting the KRAS G12C Oncoprotein

Mutations in the RAS family of oncogenes (KRAS, NRAS, HRAS) are the most common genetic alterations found in human cancers, present in approximately 30% of all tumors. The KRAS G12C mutation, which involves a glycine-to-cysteine substitution at codon 12, is a key driver of tumor growth in a significant subset of non-small cell lung cancer, colorectal cancer, and other solid tumors. For decades, KRAS was deemed "undruggable" due to the protein's smooth surface, which lacks deep hydrophobic pockets for small molecules to bind, and its picomolar affinity for its natural ligands, GTP and GDP, making competitive inhibition nearly impossible.

The paradigm shifted with the discovery of a cryptic, allosteric pocket, known as the switch-II pocket, which becomes accessible in the inactive, GDP-bound state of the KRAS protein. Crucially, in the KRAS G12C mutant, the substituted cysteine residue is located adjacent to this pocket. This unique feature provided a novel therapeutic strategy: designing small molecules that could non-covalently bind within the switch-II pocket and then form a permanent, covalent bond with the reactive thiol group of the mutant cysteine-12. Fulzerasib was developed to exploit this vulnerability.

Biochemical Activity and Pathway Inhibition

Fulzerasib functions as a potent, covalent, and irreversible inhibitor of the KRAS G12C protein. Its mechanism of action involves a two-step process. First, the molecule docks into the switch-II pocket. Then, its reactive acrylamide group forms a stable covalent bond with the cysteine-12 residue. This irreversible modification achieves a critical outcome: it

locks the KRAS G12C protein in its inactive, GDP-bound conformation.

By trapping KRAS in this "off" state, fulzerasib prevents the protein from exchanging GDP for GTP, a step that is essential for its activation. This blockade has profound downstream consequences. Activated KRAS normally functions as a molecular switch that turns on critical pro-survival signaling pathways. By inhibiting KRAS activation, fulzerasib effectively shuts down these downstream oncogenic cascades, most notably the

MAPK (RAS-RAF-MEK-ERK) and PI3K-AKT pathways. These pathways are responsible for driving key cancer hallmarks, including uncontrolled cell proliferation, survival, and differentiation. The ultimate effect of this pathway inhibition is the induction of tumor cell apoptosis (programmed cell death) and cell cycle arrest, leading to tumor regression.

The in vitro potency of fulzerasib has been quantified through various biochemical and cellular assays, demonstrating its highly efficient on-target activity :

• Inhibition of GDP/GTP nucleotide exchange on KRAS G12C: IC50​=29 nM.
• Inhibition of cellular RAS-GTP levels: IC50​=74 nM.
• Inhibition of downstream pERK signaling: IC50​=37 nM.
• Inhibition of growth in KRAS G12C-mutant tumor cell lines: IC50​=2−20 nM.

The close correlation between the potency of direct target engagement (IC50​ of 29 nM) and the inhibition of the downstream signaling marker pERK (IC50​ of 37 nM) indicates a highly efficient and direct mechanism of action. There is minimal loss of potency as the inhibitory signal is transmitted down the pathway, suggesting that locking the KRAS G12C protein is sufficient to achieve a profound and complete blockade of its oncogenic output. This biochemical efficiency is a likely contributor to the potent anti-tumor activity observed at clinically relevant doses.

Preclinical Evidence of Efficacy and Favorable Pharmacokinetics

Before advancing to human trials, fulzerasib underwent extensive preclinical evaluation that provided strong evidence of its therapeutic potential and foreshadowed its eventual clinical success. The preclinical data package demonstrated high in vitro potency and exquisite selectivity for the KRAS G12C mutant protein over the wild-type form.

A key achievement of the drug design program was the optimization of its pharmacokinetic (PK) profile. Preclinical studies in multiple animal species confirmed that fulzerasib possesses favorable oral PK properties, including low clearance, high systemic exposure, and excellent oral bioavailability. This profile ensures that effective drug concentrations can be achieved and maintained with oral dosing, a crucial feature for patient convenience and long-term treatment.

This strong PK profile translated into significant in vivo anti-tumor efficacy across a broad spectrum of patient-derived and cell-line-derived xenograft models of human cancers harboring the KRAS G12C mutation. Robust tumor growth inhibition and regression were observed in models of :

• Pancreatic cancer (MIA PaCa-2)
• Colorectal cancer (SW837)
• Non-small cell lung cancer (NCI-H358, LU2529)

A particularly compelling piece of preclinical evidence was the demonstration of significant efficacy in intracranial tumor models. This finding suggested that fulzerasib could cross the blood-brain barrier, a formidable challenge for many cancer drugs, and exert its anti-tumor effects within the central nervous system. This preclinical observation was a strong leading indicator of the clinically meaningful activity that was later confirmed in patients with brain metastases, demonstrating a highly successful and predictive translation from preclinical models to clinical reality.

Furthermore, preclinical studies provided the scientific rationale for future combination therapies. Co-administration of fulzerasib with the EGFR inhibitor cetuximab showed synergistic anti-cancer effects in NSCLC models, providing the foundational evidence that led to the design of the highly successful KROCUS clinical trial.

Clinical Efficacy Assessment Across Tumor Types

The clinical development program for fulzerasib has generated a wealth of efficacy data across multiple cancer types and treatment settings. The results have been consistently positive, culminating in regulatory approval and establishing fulzerasib as a highly active therapeutic agent. This section provides a critical analysis of the key clinical trial data that define its therapeutic value.

Monotherapy in Advanced Non-Small Cell Lung Cancer (NSCLC)

The cornerstone of fulzerasib's approval in China was the pivotal, single-arm registrational study (Phase II portion of trial NCT05005234) conducted in Chinese patients with advanced KRAS G12C-mutant NSCLC who had progressed on at least one prior line of systemic therapy. The study demonstrated robust and durable anti-tumor activity.

Based on the final analysis of 116 evaluable patients with a data cutoff of December 13, 2023, the trial met its primary efficacy endpoints, with results assessed by an Independent Radiology Review Committee (IRRC) :

• Confirmed Objective Response Rate (ORR): 49.1% (95% CI: 39.7-58.6), indicating that nearly half of these heavily pre-treated patients experienced significant tumor shrinkage.
• Disease Control Rate (DCR): 90.5% (95% CI: 83.7-95.2), showing that the vast majority of patients derived clinical benefit, including tumor shrinkage or disease stabilization.
• Median Progression-Free Survival (PFS): 9.7 months (95% CI: 5.6-11.0), representing a substantial delay in disease progression.
• Median Duration of Response (DoR): Not Reached at the time of analysis, suggesting that the responses were durable.
• Median Overall Survival (OS): Not Reached, as the data were still immature.

The consistency of these results over time builds high confidence in the drug's activity. Earlier data cuts from the same study showed a similar strong signal. For instance, an analysis presented at the 2022 Chinese Society of Clinical Oncology (CSCO) meeting, focusing on 21 patients treated at the recommended Phase 2 dose (RP2D) of 600 mg twice daily (BID), reported an investigator-assessed ORR of 61.9% and a DCR of 100%. This reproducibility of a strong efficacy signal throughout the trial's duration underscores the robustness of fulzerasib's anti-tumor effect.

Monotherapy in Metastatic Colorectal Cancer (CRC)

Fulzerasib has demonstrated particularly impressive activity as a monotherapy in metastatic CRC, an indication where first-generation KRAS G12C inhibitors have shown more limited single-agent efficacy. The data come from a pooled analysis of two Phase I studies (NCT05005234 and NCT05497336) in previously treated patients.

The pooled analysis, which included 56 patients with a data cutoff of December 13, 2023, revealed the following efficacy outcomes :

• Confirmed ORR: 44.6% (95% CI: 31.3-58.5).
• DCR: 87.5% (95% CI: 75.9-94.8).
• Median PFS: 8.1 months (95% CI: 5.5-13.8).
• Median OS: 17.0 months (95% CI: 12.6-Not Reached).
• Median DoR: 12.6 months (95% CI: 12.6-13.9).

These results are a key competitive differentiator for fulzerasib. The KRAS G12C inhibitor class has historically struggled in CRC, often requiring combination with an anti-EGFR antibody to achieve meaningful responses. The potent monotherapy ORR of nearly 45% and a median PFS of over 8 months in a refractory CRC population are substantially better than what has been reported for other single-agent KRAS G12C inhibitors. This superior single-agent backbone was a critical factor in the FDA's decision to approve a global Phase III registrational trial for fulzerasib monotherapy in this setting, signaling a potential for it to become a standard of care as a single agent.

Combination Therapy in First-Line NSCLC (KROCUS Study)

Perhaps the most striking results for fulzerasib have emerged from the KROCUS study (NCT05756153), a multi-center Phase Ib/II trial conducted in Europe. This study evaluated fulzerasib (600 mg BID) in combination with cetuximab, an anti-EGFR antibody, as a first-line treatment for patients with advanced KRAS G12C-mutant NSCLC.

The efficacy data from this trial, based on a cohort of 47 patients, have been exceptionally promising and suggest the potential for a new standard of care :

• ORR: 80.0% (among 45 evaluable patients).
• DCR: 100%.
• Median PFS: 12.5 months.
• Median OS: Not Reached.

The depth of the responses was also remarkable, with 57.8% of patients experiencing tumor shrinkage of 50% or more, and three patients achieving a complete response. These results represent a potential paradigm shift for the first-line treatment of KRAS G12C-mutant NSCLC. The current standard of care often involves immunotherapy-based regimens with or without chemotherapy. An ORR of 80% and a median PFS of 12.5 months are highly competitive with, and potentially superior to, historical benchmarks. The fact that this is achieved with a chemo-free and immune-free regimen is a significant advantage. It not only offers a potentially more effective and better-tolerated front-line option but also strategically preserves immunotherapy for use in later lines of treatment, which could extend overall survival for patients.

Intracranial Activity (Brain Metastases)

A critical area of unmet need in oncology is the treatment of brain metastases, as many drugs fail to penetrate the blood-brain barrier. Fulzerasib has shown compelling evidence of intracranial activity, consistent with preclinical findings.

In the first-line KROCUS study, 34% of enrolled patients had brain metastases at baseline. Among those who were evaluable, the systemic ORR was 71.4%. Furthermore, all non-target brain lesions either disappeared or remained stable, and all target brain lesions shrank during treatment. This demonstrates that fulzerasib, particularly in combination with cetuximab, can elicit profound responses both systemically and within the central nervous system, offering a vital therapeutic option for this high-risk patient population.

Table 2: Summary of Key Clinical Efficacy Outcomes for Fulzerasib
Indication / Setting	Trial ID(s)	Patient N	ORR (%) (95% CI)	DCR (%) (95% CI)	Median PFS (months) (95% CI)	Median OS (months) (95% CI)
2L+ NSCLC (Monotherapy)	NCT05005234	116	49.1 (39.7-58.6)	90.5 (83.7-95.2)	9.7 (5.6-11.0)	Not Reached
2L+ CRC (Monotherapy)	NCT05005234, NCT05497336	56	44.6 (31.3-58.5)	87.5 (75.9-94.8)	8.1 (5.5-13.8)	17.0 (12.6-NR)
1L NSCLC (Combo w/ Cetuximab)	NCT05756153	47	80.0 (evaluable n=45)	100	12.5	Not Reached
Data sourced from. 2L+ = Second-line or later therapy. 1L = First-line therapy.

Comprehensive Safety and Tolerability Profile

A drug's safety and tolerability are as crucial as its efficacy in determining its overall clinical value and utility. Fulzerasib has consistently demonstrated a manageable and favorable safety profile across its clinical development program, with a key differentiation from its competitors that enhances its strategic potential, particularly in combination regimens.

Adverse Events in Monotherapy (NSCLC and CRC)

In monotherapy settings, fulzerasib has been generally well-tolerated by patients with both NSCLC and CRC. Analysis of safety data from the pivotal trials (NCT05005234, NCT05497336) shows that the majority of Treatment-Related Adverse Events (TRAEs) were mild to moderate (Grade 1-2) in severity.

• In the pivotal NSCLC study (n=116), TRAEs of any grade occurred in 92.2% of patients. Grade 3 or higher TRAEs were reported in 41.4% of patients. Importantly, TRAEs led to treatment discontinuation in only 7.8% of patients, indicating that most adverse events could be managed effectively without stopping therapy.
• In the pooled CRC analysis (n=56), TRAEs occurred in 94.6% of patients, with Grade 3 TRAEs observed in 25.0%. A critical finding from this cohort was that no patients discontinued treatment due to a TRAE.

This extremely low rate of treatment discontinuation due to toxicity is a powerful indicator of the drug's clinical manageability. It suggests that when adverse events do occur, they can be effectively handled through supportive care or dose modifications (interruption or reduction), allowing patients to remain on a highly effective therapy for a longer duration. This is a crucial factor for both physician adoption and patient quality of life.

Across the monotherapy studies, the most commonly reported TRAEs included anemia, increased alanine aminotransferase (ALT), increased aspartate aminotransferase (AST), pruritus (itching), asthenia (fatigue), decreased white blood cell count, and proteinuria.

Safety Profile in Combination with Cetuximab (KROCUS Study)

The combination of fulzerasib with cetuximab in the first-line NSCLC KROCUS study also demonstrated a highly favorable and manageable safety profile. No new or unexpected safety signals were identified, and the adverse event profile was consistent with the known toxicities of each individual agent.

• TRAEs occurred in 87.2% of patients, with the vast majority being Grade 1-2.
• Grade 3 TRAEs were reported in only 14.9% of patients.
• Critically, no Grade 4 or 5 (fatal) TRAEs were observed.

A surprising and highly positive finding from the KROCUS study was that the incidence of Grade 3 or higher TRAEs in the combination therapy (14.9%) was reported to be "considerably lower" than that observed in fulzerasib monotherapy for second-line NSCLC. While counter-intuitive, as combinations are often expected to be more toxic, this result strongly de-risks the first-line strategy. A regimen that is both highly effective and exceptionally well-tolerated represents an ideal therapeutic option, and this finding bolsters the case for the fulzerasib-cetuximab combination as a potential new standard of care.

Comparative Safety and Management

A detailed analysis of fulzerasib's safety profile reveals a key strategic advantage over other approved KRAS G12C inhibitors: a differentiated and more favorable gastrointestinal (GI) toxicity profile.

Pooled analysis of the CRC data explicitly noted that fulzerasib was associated with a significantly lower incidence of GI events like nausea and diarrhea compared to both sotorasib and adagrasib. As shown in Table 3, this distinction is stark and clinically meaningful. This favorable GI profile is likely a direct consequence of fulzerasib's unique chemical structure and optimized pharmacokinetic properties. This advantage is critical, as it not only improves patient quality of life but also makes fulzerasib an ideal backbone for combination therapies, where minimizing overlapping toxicities with other agents (such as chemotherapy or other targeted therapies) is paramount.

While anemia was a common TRAE, particularly in the CRC monotherapy setting (50.0% any grade), the incidence of severe (Grade 3) anemia was 7.1%, which is comparable to its competitors. Importantly, this side effect proved to be manageable with supportive care and did not lead to treatment discontinuations.

Table 3: Comparative Safety Profile of Fulzerasib vs. Other KRAS G12C Inhibitors
Treatment-Related Adverse Event	Fulzerasib (CRC Mono)	Fulzerasib + Cetuximab (NSCLC)	Sotorasib (CRC Mono)	Adagrasib (CRC Mono)
Diarrhea (Any Grade)	1.8%	13%	21.0%-34.0%	66%
Nausea (Any Grade)	3.6%	26%	Not specified	49.2%-76%
Anemia (Any Grade)	50.0%	9%	13.2%	16%
Anemia (Grade ≥3)	7.1%	0%	4.7%	9%
Data for fulzerasib and comparisons sourced from. Competitor data represents ranges from published literature as cited in the source material. CRC Mono = Colorectal Cancer Monotherapy. NSCLC = Non-Small Cell Lung Cancer.

Regulatory Trajectory and Strategic Positioning

Fulzerasib's journey from a clinical candidate to an approved therapy has been characterized by a rapid and assertive regulatory strategy, reflecting the high quality of its clinical data and the significant unmet need it addresses. Its entry into the market positions it as a major competitor in the evolving landscape of KRAS G12C inhibitors.

Global Regulatory Milestones

Fulzerasib has achieved several key regulatory milestones in major global markets, underscoring its clinical importance and commercial potential.

• China (National Medical Products Administration - NMPA):
• Breakthrough Therapy Designation (BTD): The NMPA granted two separate BTDs to fulzerasib, a designation that expedites the review of drugs for serious conditions with promising preliminary evidence. It received BTD for the treatment of previously treated, advanced NSCLC in January 2023, and for previously treated, advanced CRC in May 2023.
• NDA Acceptance and Priority Review: The New Drug Application (NDA) for NSCLC was accepted by the NMPA's Center for Drug Evaluation (CDE) in November 2023 and was granted Priority Review status.
• Market Approval: In August 2024, the NMPA officially approved fulzerasib, marketed as Dupert®, for the treatment of adult patients with advanced NSCLC harboring the KRAS G12C mutation who have received at least one prior systemic therapy.
• United States (Food and Drug Administration - FDA):
• Phase III Trial Approval: In April 2024, the FDA granted approval for GenFleet to proceed with a global, multi-center, randomized, open-label Phase III registrational study. This trial will evaluate fulzerasib monotherapy against the standard of care in patients with refractory metastatic CRC. The decision to pursue a monotherapy registration path in CRC is a bold move, signaling immense confidence in its differentiated efficacy in this setting.
• Europe (European Medicines Agency - EMA):
• Clinical Trial Approval: The EMA approved the initiation of the Phase Ib/II KROCUS study, which is being conducted across multiple European sites to evaluate fulzerasib in combination with cetuximab for first-line NSCLC.

Competitive Landscape Analysis

Fulzerasib enters the market as the third globally approved KRAS G12C inhibitor, following sotorasib (developed by Amgen) and adagrasib (developed by Mirati Therapeutics, now part of Bristol Myers Squibb). It holds the distinction of being the first such inhibitor developed in China. An objective comparison of its clinical data against the pivotal trial data of its predecessors suggests that fulzerasib is not just a "me-too" drug but is positioned to be a potential best-in-class agent.

• Efficacy Comparison:
• NSCLC Monotherapy: Fulzerasib's confirmed ORR of 49.1% and median PFS of 9.7 months in second-line NSCLC appear numerically superior to the pivotal data that supported the approvals of sotorasib (ORR 37.1%, mPFS 6.8 months) and adagrasib (ORR 42.9%, mPFS 6.5 months) in similar patient populations.
• CRC Monotherapy: The differentiation is even more pronounced in colorectal cancer. Fulzerasib's confirmed ORR of 44.6% as a single agent is substantially higher than the monotherapy response rates reported for sotorasib (approximately 10%) and adagrasib (approximately 20%) in CRC. This supports the assertion that its efficacy is superior in this indication.
• First-Line NSCLC Combination: The KROCUS study's ORR of approximately 80% with cetuximab sets an extremely high efficacy benchmark that will be challenging for other combination strategies currently in development to meet.
• Safety Comparison: As detailed in Section V and Table 3, fulzerasib's more favorable gastrointestinal safety profile is a key competitive advantage. This improved tolerability could lead to better patient compliance and make it the preferred agent for use in combination regimens.

This combination of superior efficacy and a differentiated safety profile positions fulzerasib not just to compete with, but potentially to displace the existing KRAS G12C inhibitors. The clinical data package provides a compelling argument for its adoption as the preferred agent in its class, which could enable it to capture significant market share from the first-to-market drugs.

Future Directions and Unmet Clinical Needs

The development of fulzerasib is ongoing, with several key initiatives poised to further expand its clinical utility and market potential.

• Global CRC Registrational Trial: The ongoing global Phase III monotherapy trial in CRC (GFH925X0301) is a major value-inflection point. A positive outcome in this randomized trial would solidify its position as a standard of care for this patient population worldwide.
• Novel Combination Strategies: The development pipeline includes plans for a Phase II study combining fulzerasib with ivonescimab (AK-112), a novel PD-1/VEGF bispecific antibody, for the first-line treatment of NSCLC. This represents another promising chemo-free combination strategy that could further enhance its efficacy.
• Addressing Unmet Needs: Fulzerasib addresses a significant unmet clinical need for patients with KRAS G12C-mutated cancers, who historically have had poor prognoses and limited effective treatment options after progressing on first-line therapies. Its proven efficacy in patients with brain metastases is particularly important, as this is a common and difficult-to-treat site of disease progression.

Concluding Analysis and Expert Outlook

Fulzerasib (GFH-925) has emerged as a significant advancement in the targeted therapy of KRAS-mutant cancers. Its development journey, from a rationally designed novel chemical scaffold to a clinically validated and regulatory-approved therapeutic, exemplifies a successful, data-driven approach to modern drug discovery. The comprehensive body of evidence establishes a clear and compelling value proposition based on three foundational pillars: a unique molecular structure, potentially best-in-class clinical efficacy, and a differentiated, highly manageable safety profile.

The synthesis of the available data indicates that fulzerasib has a high probability of continued clinical and commercial success. Its recent approval in China provides a strong commercial foothold in a major market, while the ongoing and planned global trials position it for successful entry into the lucrative US and European markets. The clinical results, particularly the striking efficacy of the cetuximab combination in first-line NSCLC and the robust monotherapy activity in CRC, suggest that fulzerasib has the potential to become a new standard of care in multiple settings. Its superior single-agent backbone and favorable safety profile make it a versatile asset, ideal for both monotherapy and as a preferred partner in future combination regimens, ensuring a robust strategy for life-cycle management and label expansion.

In conclusion, fulzerasib is not merely another entrant into the KRAS G12C inhibitor class; it is a formidable competitor poised to lead the second wave of therapies targeting this critical oncogene. Its future impact on the oncology landscape will be defined by the outcomes of its ongoing global Phase III trial in colorectal cancer and its ability to redefine the first-line treatment paradigm in non-small cell lung cancer. Based on the strength and consistency of the data to date, fulzerasib represents a pivotal development, offering the promise of more effective and better-tolerated treatment options for patients with KRAS G12C-mutated cancers worldwide.

Works cited

1. fulzerasib | Ligand page - IUPHAR/BPS Guide to PHARMACOLOGY, accessed September 13, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=clinical&ligandId=12393
2. What clinical trials have been conducted for Fulzerasib? - Patsnap Synapse, accessed September 13, 2025, https://synapse.patsnap.com/article/what-clinical-trials-have-been-conducted-for-fulzerasib
3. GFH925 (KRAS G12C Inhibitor) Granted with Breakthrough Therapy ..., accessed September 13, 2025, http://www.genfleet.com/en/press_release-54
4. Promising Phase II Efficacy & Safety Data from KROCUS Study Indicate Potential of fulzerasib (KRAS G12C Inhibitor) in Combination with cetuximab as Next-generation First-line NSCLC Standard-or-care: GenFleet Therapeutics Announces Latest Findings in a Late-breaking Abstract at the Mini Oral Presentation of 2025 ELCC Annual Meeting, accessed September 13, 2025, http://www.genfleet.com/en/press_release-84
5. GenFleet Therapeutics Announces Efficacy & Safety Result from Phase II Trial for First-line NSCLC Treatment in KROCUS Study, fulzerasib (KRAS G12C Inhibitor) in Combination with cetuximab, in a Late-breaking Abstract at the Oral Presentation of 2024 ASCO Annual Meeting, accessed September 13, 2025, http://www.genfleet.com/en/press_release-76
6. GenFleet Announces the First Approval of a KRAS G12C Inhibitor in China for Treatment of Advanced Non-small Cell Lung Cancer Patients Harboring KRAS G12C Mutation, accessed September 13, 2025, http://www.genfleet.com/en/press_release-80
7. Efficacy and Safety of KRASG12C Inhibitor IBI351 Monotherapy in Patients With Advanced NSCLC: Results From a Phase 2 Pivotal Study - PubMed, accessed September 13, 2025, https://pubmed.ncbi.nlm.nih.gov/39127176/
8. Efficacy and safety of IBI351 (fulzerasib) monotherapy in ..., accessed September 13, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12297441/
9. Fulzerasib Displays Efficacy and Tolerability in KRAS G12C ..., accessed September 13, 2025, https://www.onclive.com/view/fulzerasib-displays-efficacy-and-tolerability-in-kras-g12c-mutated-metastatic-crc
10. GenFleet Announces the First Approval of a KRAS G12C Inhibitor in China for Treatment of Advanced Non-small Cell Lung Cancer Patients Harboring KRAS G12C Mutation - FirstWord Pharma, accessed September 13, 2025, https://firstwordpharma.com/story/5888578
11. FDA approves phase III trial of GenFleet's KRAS G12C inhibitor, accessed September 13, 2025, https://www.clinicaltrialsarena.com/news/fda-phase-iii-genfleets-kras/
12. GenFleet Therapeutics Secures FDA Approval for Pioneering Phase III KRAS G12C Inhibitor Trial in Colorectal Cancer - BioPharma APAC, accessed September 13, 2025, https://biopharmaapac.com/news/79/4669/genfleet-therapeutics-secures-fda-approval-for-pioneering-phase-iii-kras-g12c-inhibitor-trial-in-colorectal-cancer.html
13. Fulzerasib (IBI351, GFH925) | KRAS G12C inhibitor | Probechem Biochemicals, accessed September 13, 2025, http://www.probechem.com/products_Fulzerasib.html
14. fulzerasib | Ligand page - IUPHAR/BPS Guide to PHARMACOLOGY, accessed September 13, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=12393
15. Discovery of Fulzerasib (GFH925) for the Treatment of KRAS G12C-Mutated Solid Tumors, accessed September 13, 2025, https://pubmed.ncbi.nlm.nih.gov/40701936/
16. Fulzerasib (IBI351) | KRAS Inhibitor - MedchemExpress.com, accessed September 13, 2025, https://www.medchemexpress.com/fulzerasib.html
17. Discovery and preclinical characterization of KRAS G12C inhibitor fulzerasib (GFH925) for advanced solid tumors - ACS Fall 2025 - American Chemical Society, accessed September 13, 2025, https://acs.digitellinc.com/live/35/session/569765
18. fulzerasib | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY, accessed September 13, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=structure&ligandId=12393
19. Innovent Biologics Pays GenFleet $22M Upfront for Rights to KRAS G12C Inhibitor in Greater China | Precision Oncology News, accessed September 13, 2025, http://www.genfleet.com/en/media_coverage-34
20. Innovent and GenFleet Announce Exclusive Global License Agreement for GFH925 (KRAS G12C Inhibitor) - PR Newswire, accessed September 13, 2025, https://www.prnewswire.com/news-releases/innovent-and-genfleet-announce-exclusive-global-license-agreement-for-gfh925-kras-g12c-inhibitor-301367323.html
21. A Study of GFH925 in Combination With Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation | MedPath, accessed September 13, 2025, https://trial.medpath.com/clinical-trial/7cc6640f926d58e4/safety-tolerability-pharmacokinetics-efficacy-GFH925-cetuximab-advanced-NSCLC-KRAS-G12C
22. Discovery of Fulzerasib (GFH925) for the Treatment of KRAS G12C ..., accessed September 13, 2025, https://pubs.acs.org/doi/abs/10.1021/acs.jmedchem.4c03183
23. China's First NDA for a KRAS G12C Inhibitor: NMPA Accepts New Drug Application for GFH925 and Grants GFH925 with Priority Review Designation - BioSpace, accessed September 13, 2025, https://www.biospace.com/china-s-first-nda-for-a-kras-g12c-inhibitor-nmpa-accepts-new-drug-application-for-gfh925-and-grants-gfh925-with-priority-review-designation
24. Discovery of a Covalent Inhibitor of KRASG12C (AMG 510) for the Treatment of Solid Tumors | Journal of Medicinal Chemistry - ACS Publications, accessed September 13, 2025, https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01180
25. JDQ443, a Structurally Novel, Pyrazole-Based, Covalent Inhibitor of KRASG12C for the Treatment of Solid Tumors | Journal of Medicinal Chemistry - ACS Publications, accessed September 13, 2025, https://pubs.acs.org/doi/10.1021/acs.jmedchem.2c01438
26. GenFleet Therapeutics Announces FDA's Clinical Trial Approval for GFH925 (KRAS G12C Inhibitor) Monotherapy in Phase III Registrational Study Treating Metastatic Colorectal Cancer - PR Newswire, accessed September 13, 2025, https://www.prnewswire.com/news-releases/genfleet-therapeutics-announces-fdas-clinical-trial-approval-for-gfh925-kras-g12c-inhibitor-monotherapy-in-phase-iii-registrational-study-treating-metastatic-colorectal-cancer-302121725.html
27. KROCUS: A phase II study investigating the efficacy and safety of fulzerasib (GFH925) in combination with cetuximab in patients with previously untreated advanced KRAS G12C mutated NSCLC. - ASCO Publications, accessed September 13, 2025, https://ascopubs.org/doi/10.1200/JCO.2024.42.17_suppl.LBA8511
28. NCT05005234 | A Study of GFH925 in Patients With Advanced Solid Tumors With KRAS G12C Mutations | ClinicalTrials.gov, accessed September 13, 2025, https://clinicaltrials.gov/study/NCT05005234
29. A Study of GFH925 in Patients With Advanced Solid Tumors With KRAS G12C Mutations, accessed September 13, 2025, https://clin.larvol.com/trial-detail/NCT05005234
30. Fulzerasib Receives Approval in China for Advanced KRAS G12C+ ..., accessed September 13, 2025, https://www.cancernetwork.com/view/fulzerasib-receives-approval-in-china-for-advanced-kras-g12c-nsclc
31. Efficacy and safety of IBI351 (GFH925) monotherapy in metastatic ..., accessed September 13, 2025, https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.3586
32. Efficacy and safety of IBI351 (GFH925) monotherapy in metastatic colorectal cancer harboring KRASG12C mutation: Preliminary results from a pooled analysis of two phase I studies. - ASCO, accessed September 13, 2025, https://www.asco.org/abstracts-presentations/ABSTRACT415198
33. GenFleet Therapeutics Announces FDA's Clinical Trial Approval for GFH925 (KRAS G12C Inhibitor) Monotherapy in Phase III Registrational Study Treating Metastatic Colorectal Cancer, accessed September 13, 2025, http://www.genfleet.com/en/press_release-75
34. Frontline Fulzerasib Plus Cetuximab Elicits Deep, Durable ... - OncLive, accessed September 13, 2025, https://www.onclive.com/view/frontline-fulzerasib-plus-cetuximab-elicits-deep-durable-responses-in-kras-g12c-mutated-nsclc
35. Phase I dose-escalation study of IBI351 (GFH925) monotherapy in patients with advanced solid tumors. | Journal of Clinical Oncology - ASCO Publications, accessed September 13, 2025, https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.3110
36. Phase I Data for GFH925 Monotherapy Presented at 2023 AACR-GenFleet Therapeutics, accessed September 13, 2025, http://www.genfleet.com/en/press_release-57
37. Innovent Announces Updated Data of Phase 1 Clinical Trial for IBI351 (KRAS[G12C] Inhibitor) as Monotherapy for Solid Tumors at the AACR Annual Meeting 2023 - BioSpace, accessed September 13, 2025, https://www.biospace.com/innovent-announces-updated-data-of-phase-1-clinical-trial-for-ibi351-kras-g12c-inhibitor-as-monotherapy-for-solid-tumors-at-the-aacr-annual-meeting-2023
38. GFH-925 Not Yet Recruiting Phase 2 Trials for KRAS G12C Lung Cancer Treatment, accessed September 13, 2025, https://go.drugbank.com/drugs/DB17481/clinical_trials?conditions=DBCOND0167529&phase=2&purpose=treatment&status=not_yet_recruiting